Physician profile
Abul K Azad
NPI 1003979121
$20,140.59
in general payments reported to CMS, 2019-2025
37 companies · $2,011 in 2025
The $2,011 reported for 2025 was more than what 76% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,464 · 2020: $1,062 · 2021: $1,581 · 2022: $2,754 · 2023: $2,504 · 2024: $2,764 · 2025: $2,011.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,179 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,179.03 |
| Education | $100.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $7,316.70 | 2019-2025 | Prolastin-C Liquid, Gamunex-C, Xembify |
| Glaxosmithkline, LLC. | $3,877.53 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $3,693.39 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Genzyme Corporation | $886.60 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $704.99 | 2019-2025 | Ofev |
| Regeneron Healthcare Solutions, INC. | $512.97 | 2021-2024 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $454.54 | 2021-2025 | Glassia, Cuvitru |
| Harmony Biosciences LLC | $431.14 | 2023-2024 | Wakix |
| Amgen INC. | $329.34 | 2024-2025 | Tezspire |
| Electromed, INC. | $214.40 | 2019-2025 | Smartvest |
| Pfizer INC. | $197.41 | 2021-2025 | |
| Actelion Pharmaceuticals US, INC. | $169.18 | 2023-2024 | Uptravi, Opsumit |
| United Therapeutics Corporation | $143.77 | 2022 | |
| Verona Pharma, INC. | $138.08 | 2025 | Ohtuvayre |
| Jazz Pharmaceuticals INC. | $122.89 | 2019-2022 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abul Azad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.